Ovarian cancer accounts for 4% of all cancers in women and is the leading cause of death
from gynaecologic malignancies. Because early-stage ovarian cancer is generally …

Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal
gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic …

Ovarian cancer is the second most common gynaecological malignancy, and represents the
leading cause of gynecologic cancer-related death in Europe and United States. The …

Ovarian cancer is the fifth most common cause of death from cancer in women. The standard
first-line treatment for advanced ovarian cancer is a combination of paclitaxel and …

The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line
surgery and chemotherapy. There are two subgroups of patients with recurrent ovarian …

Objectives. The aim of this study was to evaluate long-term results and to assess prognostic
factors which have an impact on overall survival in patients with epithelial ovarian cancer …

Until the mid-1970s, standard therapy for ovarian carcinoma was a single alkylating agent.
Subsequently, combination chemotherapy was shown to be superior to such therapy. During …

Although notable progress has been made in the treatment of epithelial ovarian cancer, the
majority of patients with advanced disease still experience recurrence that ultimately results …

Background Ovarian cancer is treated with surgery followed by combination chemotherapy
with paclitaxel plus carboplatin. In an effort to improve outcomes, clinical trials are evaluating …

Background Patients with ovarian cancer usually present to a family physician with
nonspecific symptoms, most often abdominal pain. The outcome depends above all on the …